CN116133642A - 包含聚合物组合制备剂的制备剂和组合物 - Google Patents

包含聚合物组合制备剂的制备剂和组合物 Download PDF

Info

Publication number
CN116133642A
CN116133642A CN202180062155.6A CN202180062155A CN116133642A CN 116133642 A CN116133642 A CN 116133642A CN 202180062155 A CN202180062155 A CN 202180062155A CN 116133642 A CN116133642 A CN 116133642A
Authority
CN
China
Prior art keywords
preparation
polymer
polymer combination
poloxamer
immunomodulatory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180062155.6A
Other languages
English (en)
Chinese (zh)
Inventor
M·S·戈尔德伯格
P·A·科诺维兹
I·X·陈
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sage Therapy
Original Assignee
Sage Therapy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sage Therapy filed Critical Sage Therapy
Publication of CN116133642A publication Critical patent/CN116133642A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
CN202180062155.6A 2020-07-17 2021-07-17 包含聚合物组合制备剂的制备剂和组合物 Pending CN116133642A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063053488P 2020-07-17 2020-07-17
US63/053,488 2020-07-17
US202063108861P 2020-11-02 2020-11-02
US63/108,861 2020-11-02
PCT/US2021/042110 WO2022016129A1 (en) 2020-07-17 2021-07-17 Preparations and compositions comprising polymer combination preparations

Publications (1)

Publication Number Publication Date
CN116133642A true CN116133642A (zh) 2023-05-16

Family

ID=79555039

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180062155.6A Pending CN116133642A (zh) 2020-07-17 2021-07-17 包含聚合物组合制备剂的制备剂和组合物

Country Status (10)

Country Link
US (1) US20230293427A1 (https=)
EP (1) EP4181857A4 (https=)
JP (1) JP2023534504A (https=)
KR (1) KR20230041032A (https=)
CN (1) CN116133642A (https=)
AU (1) AU2021308083A1 (https=)
BR (1) BR112023000190A2 (https=)
CA (1) CA3187174A1 (https=)
IL (1) IL299806A (https=)
WO (1) WO2022016129A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116322702A (zh) * 2020-08-17 2023-06-23 萨吉治疗公司 用于癌症治疗的髓源性抑制性细胞功能的免疫调节
CN117619361A (zh) * 2023-12-09 2024-03-01 中北大学 改性高岭土/包覆型高铁酸钾复合材料及其制备方法

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114617903B (zh) * 2022-03-15 2024-05-24 中国人民解放军总医院第一医学中心 一种用于血浆冻干的组合物及其应用
KR20250030440A (ko) * 2022-04-29 2025-03-05 바이오데벡 인코포레이티드 생체적합성 접착제 물질 및 사용 방법
IT202300004218A1 (it) * 2023-03-07 2024-09-07 Delim Cosmetics & Pharma S R L Composizioni termoreversibili e mucoadesive
CN116554949A (zh) * 2023-05-16 2023-08-08 广州大学 一种润滑油添加剂及其制备方法
CN120324357B (zh) * 2025-06-03 2025-10-24 上海国创医药股份有限公司 一种普瑞巴林缓释组合物及其制备方法

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997000275A2 (en) * 1995-06-16 1997-01-03 Gel Sciences, Inc. Responsive polymer networks and methods of their use
JP2002516617A (ja) * 1995-06-16 2002-06-04 メドロジック グローバル コーポレイション 反応性ポリマー網状構造体及びその使用法
CN101297973A (zh) * 2008-05-22 2008-11-05 武汉华纳生物工程有限公司 高生物粘附温敏水凝胶及其制备方法和用途
CN103055304A (zh) * 2013-01-19 2013-04-24 卓阳 一种治疗皮肤溃疡用复方温敏凝胶剂及其制备方法
CN104983722A (zh) * 2015-07-01 2015-10-21 苏州吉欧生物科技有限公司 一种皮肤祛疤修复喷膜剂的组合物及其制备方法
CN109820816A (zh) * 2019-02-18 2019-05-31 江苏拓弘生物科技有限公司 温度敏感性生物凝胶制剂及其应用
KR102067490B1 (ko) * 2019-05-21 2020-01-20 주식회사 티젤바이오 서방성 약물전달용 온도상전이 나노 입자/하이드로젤 복합체

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2401239A1 (en) * 2000-03-03 2001-09-13 Valentis, Inc. Improved poloxamer and poloxamine compositions for nucleic acid delivery
US20060034889A1 (en) * 2004-08-16 2006-02-16 Macromed, Inc. Biodegradable diblock copolymers having reverse thermal gelation properties and methods of use thereof
WO2010088924A1 (en) * 2009-02-06 2010-08-12 Telormedix Sa Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
EP2520279A1 (en) * 2011-05-02 2012-11-07 TERES S.r.l. Thermoreversible gel pharamaceutical compositions for odontoiatric use
US9364545B2 (en) * 2014-06-19 2016-06-14 Taipei Medical University Thermosensitive injectable hydrogel for drug delivery
EP3706718A1 (en) * 2017-11-07 2020-09-16 Royal College of Surgeons in Ireland A thermo-responsive hydrogel for intratumoral administration as a treatment in solid tumor cancers
CN113766929A (zh) * 2019-05-02 2021-12-07 斯蒂米特公司 癌症治疗
US12090205B2 (en) * 2019-10-28 2024-09-17 Rochal Technologies Llc Poloxamer compositions with reduced sol-gel transition temperatures and methods of reducing the sol-gel transition temperature of poloxamer compositions

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997000275A2 (en) * 1995-06-16 1997-01-03 Gel Sciences, Inc. Responsive polymer networks and methods of their use
JP2002516617A (ja) * 1995-06-16 2002-06-04 メドロジック グローバル コーポレイション 反応性ポリマー網状構造体及びその使用法
CN101297973A (zh) * 2008-05-22 2008-11-05 武汉华纳生物工程有限公司 高生物粘附温敏水凝胶及其制备方法和用途
CN103055304A (zh) * 2013-01-19 2013-04-24 卓阳 一种治疗皮肤溃疡用复方温敏凝胶剂及其制备方法
CN104983722A (zh) * 2015-07-01 2015-10-21 苏州吉欧生物科技有限公司 一种皮肤祛疤修复喷膜剂的组合物及其制备方法
CN109820816A (zh) * 2019-02-18 2019-05-31 江苏拓弘生物科技有限公司 温度敏感性生物凝胶制剂及其应用
KR102067490B1 (ko) * 2019-05-21 2020-01-20 주식회사 티젤바이오 서방성 약물전달용 온도상전이 나노 입자/하이드로젤 복합체

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
温辉梁等: "《生物化工产品生产技术》", 31 December 2004, 江西科学技术出版社, pages: 173 - 174 *
薛巍等: "《生物医用水凝胶》", 31 December 2012, 暨南大学出版社, pages: 198 - 200 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116322702A (zh) * 2020-08-17 2023-06-23 萨吉治疗公司 用于癌症治疗的髓源性抑制性细胞功能的免疫调节
CN117619361A (zh) * 2023-12-09 2024-03-01 中北大学 改性高岭土/包覆型高铁酸钾复合材料及其制备方法

Also Published As

Publication number Publication date
EP4181857A1 (en) 2023-05-24
WO2022016129A1 (en) 2022-01-20
CA3187174A1 (en) 2022-01-20
EP4181857A4 (en) 2024-08-14
JP2023534504A (ja) 2023-08-09
IL299806A (en) 2023-03-01
BR112023000190A2 (pt) 2023-04-25
KR20230041032A (ko) 2023-03-23
US20230293427A1 (en) 2023-09-21
AU2021308083A1 (en) 2023-01-19

Similar Documents

Publication Publication Date Title
CN116133642A (zh) 包含聚合物组合制备剂的制备剂和组合物
AU2024267047B2 (en) Degradable hyaluronic acid hydrogels
US20230398146A1 (en) Immune modulation of myeloid derived suppressive cell function for cancer treatment
JP2022531184A (ja) がんの処置
US20240082236A1 (en) Cancer therapy
US20250049951A1 (en) Nucleic acid compositions and uses thereof
P Venkatesh et al. In situ gels based drug delivery systems
Aderibigbe Design and application of injectable gels in tissue engineering and drug delivery
WO2023107371A1 (en) Solid forms of resiquimod and formulations thereof
HK40056414A (en) Degradable hyaluronic acid hydrogels

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination